Laddar...
Potential targets for pancreatic cancer immunotherapeutics
Pancreatic adenocarcinoma is the fourth leading cause of cancer death with an overall 5-year survival of less than 5%. As there is ample evidence that pancreatic adenocarcinomas elicit antitumor immune responses, identification of pancreatic cancer-associated antigens has spurred the development of...
Sparad:
| Huvudupphovsmän: | , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2011
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3148788/ https://ncbi.nlm.nih.gov/pubmed/21463193 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/imt.11.10 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|